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Important advances have been made within the past 
several years in understanding diseases at the molecu­
lar and cellular levels, which may enable the applica­
tion of somatic gene therapy to a wide variety of ge­
netic and acquired diseases. The initial clinical trials 
involving somatic gene therapy have demonstrated 
that gene transfer into human subjects can be per­
formed safely and with public acceptance. This review 
focuses on use of the epidermis as a target tissue for 
O f all the recent advances in novel pharmacologic or surgical therapeutics, it is the potential for gene therapy that has captured the interest and imagina­tion of both the scientific and public communities. Gene therapy is defined simply as the introduction 
of an exogenous gene into a host cell (transduction) to achieve a 
therapeutic benefit [1]. Although often thought applicable to the 
treatment of inherited diseases, this approach is also being applied to 
acquired diseases, ranging from cardiovascular disorders to cancer 
[1,2]. The ability to attempt this form of therapy derives from the 
progress made over the past decade in recombinant DNA technol­
ogyand cell biology. By employing these techniques, important 
advances have been made in understanding diseases at the molecular 
and cellular levels, in identifying factors that regulate gene expres­
sion, and in methods for gene transfer. Yet whereas there remain 
significant problems facing practical gene therapy (reviewed in [2]), 
various protocols have been proposed and approved for clinical trials 
with surprising rapidity. Most notably, the treatment of malignant 
melanoma by infusion of tumor infiltrating lymphocytes engi­
neered to excrete large amounts of tumor necrosis factor [3]; and 
treatment of adenosine deaminase (ADA) deficiency, a rare genetic 
disease where patients lack the ADA gene, by reintroducing cul­
tured T lymphocytes that have been transduced with a normal copy 
of the ADA gene [4]. Both these protocols require an ex vivo ap­
proach, ie somatic cells are cultured in vitro, the gene introduced, 
and then modified cells returned to the body. Therefore, it would be 
most advantageous to develop in vivo gene therapy and numerous 
experimental techniques are currently under intense investigation 
in many laboratories. 
In this chapter, we will discuss the use of the epidermis as a target 
tissue for gene therapy and assess the various delivery systems avail­
able for both ex vivo and in viVQ approaches. We will also highlight 
the use of endogenous promoters that may result in differentiation 
specific or inducible expression, and evaluate some of the diseases 
that may be treated by an epidermal approach. Finally, we will 
consider the safety aspects and the advantages of employing trans-
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gene therapy and assesses various delivery systems for 
both ex vivo and in vivo approaches. In addition, we 
discuss candidate diseases that may be amenable to epi­
dermal gene therapy and the advantages of employing 
transgenic mouse model systems to test the efficacy of 
a given gene therapy prior to clinical trials. Key words: 
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genic mouse model systems to test the efficacy of a given gene 
therapy prior to clinical trials. 
ADVANTAGES OF EMPLOYING THE EPIDERMIS FOR 
GENE THERAPY 
There are several attractive reasons for considering the epidermis as 
a target tissue for gene therapy. First and foremost is the accessibility 
of this tissue. Aside from the ease of administering a potential in vivo 
therapeutic approach, the ability to monitor the treatment site and, 
if necessary, easily remove the genetically modified area, is an ad­
vantage for safety considerations not readily available for other tis­
sues. The epidermis, being a stratified epithelium, is continuously 
renewed throughout the adult life span through the proliferative 
stem cells. Therefore, the potential to transduce the epidermal stem 
cell creates the very attractive possibility of achieving long-term 
treatment. A stratified epithelium also allows the possibility of tar­
geting gene expression to either differentiated or proliferative cells, 
depending upon disease requirements. Another distinct advantage is 
that the biology of the epidermis is relatively well characterized, at 
both the cellular and molecular levels. The conditions for culture of 
primary human keratinocytes have been defined ([5], below), and 
many of the proliferative and differentiation specific genes have 
been characterized [6]. The regulatory sequences of some of these 
genes, e.g., the keratins, have already been employed to express a 
variety of exogenous genes in the epidermis of transgenic mice 
[7 - 9] and are therefore readily adaptable for gene therapy applica­
tions. The use of specific epidermal promoters as vectors to express 
exogenous genes, results in both high levels of expression and ke­
ratinocyte specificity. 
Epidermal gene therapy is envisaged to be generally applicable to 
the treatment of a wide variety of diseases. Obviously, it will be 
employed to treat acquired or genetic diseases of the epidermis, 
especially where expression of a single gene product could alleviate 
the symptoms. Thus, a hyperproliferative skin disease, such as pso­
riasis, could be treated with an inhibitor of keratinocyte growth, 
e.g., transforming growth factor P (TGFfJ) expressed from a kera­
tin-based targeting vector [10]. Alternatively, a genetic skin disease, 
such as epidermolytic hyperkeratosis, that is caused by a point muta­
tion in either kerain Kl or KI0 (reviewed in [11]), could be treated 
by vectors designed to inhibit expression of the mutant allele, or 
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Figure 1. A schematic of an I!X 11;110 approach to epidermal gene 
therapy. Keratinocytes are cultured in vitro from a small skin biopsy. Once 
sufficient numbers are obtained, the keratinocytes are reseeded at a density 
that ensures high numbers of proliferating cells for transduction by a retro­
viral vector that contains the therapeutic gene of interest as well as the 
neomycin resistance gene. A brief selection in the neomycin analog G418 
ensures the survival of transduced cells only, which are then grown to 
confluence. Treatment of cultures with dispase releases the keratinocytes as 
an epithelial sheet that is then returned to the patient as an autograft. 
potentially , by over-expression of the normal keratin gene to ame­
liorate the condition (below). As the epidermis is known to secrete a 
variety of cytokines [12] and growth factors [13]' it may become a 
useful bioreactor, geared to the secretion of gene products that have 
a local or systemic effect. This has an obvious potential for the 
treatment of diseases such as hemophilia (below). Conversely, the 
epidermis could be engineered to act as a metabolic waste disposal 
unit for circulating toxins. Indeed, introduction of the ADA gene 
[4] into keratinocytes, which could then metabolize circulating de­
oxyadenosine, has been proposed for the treatment of ADA [14]. 
Finally, there is an emerging epidemic of melanoma and squamous 
cell carcinoma [15]; thus development of gene therapy protocols for 
skin cancer is an important goal. 
EX VIVO AND IN VIVO GENE DELIVERY SYSTEMS 
The method of gene transfer is currently the biggest hurdle-limit­
ing application of this technology. Gene delivery must be highly 
efficient, otherwise the non-transduced cells limit the effectiveness 
of the genetically altered cells. Also, a high efficiency is required to 
achieve transduction of the keratinocyte stem cells that are present 
in low numbers. It is desirable to transduce sufficient numbers of 
stem cells to minimize repeated treatments and thereby increase cost 
effectiveness. Once into a cell, the exogenous gene must integrate 
into the host genome, or alternatively exist as a stable, replicating 
episome similar to papilloma viruses [16]. If this is not achieved, 
then the introduced gene would be eventually lost due to either 
degradation or deletion following repeated mitoses. Stem cell trans­
duction and gene integration are geared to achieve long term per­
sistence of the therapeutic gene and, to date, although some results 
are encouraging [14], this has yet to be fully achieved. There are 
basically two avenues of gene delivery: an ex vivo approach, which to 
date has been the most intensively studied and is likely to be applica­
ble in the near future, and development of an in vivo approach that is 
the more desirable, but will require greater study. Each technique 
has advantages and disadvantages and specific requirements for op­
timal gene delivery. As detailed below, a major effort is underway to 
develop and refine these techniques. 
Ex vivo Gene Therapy: Transduction of Cultured Keratino­
cytes by Retrovirus Gene Delivery The ex vivo approach re­
quires culture of the patient's cells that are transduced in vitro, and 
then the genetically altered cells are returned to the patient (Fig 1). 
Often, the requirement for primary cell culture is considered one of 
the disadvantages of this approach. However, the epidermis is ide­
ally suited to an ex vivo approach, as the culture conditions have been 
THE JOURNAL OF INVESTIGATIVE DERMATOLOGY 
dearly defined [5]. Keratinocytes are usually co-cui tured using irra· 
diated fibroblasts as a feeder layer t51. Using this system, large num· 
bers of keratinocytes can be generated from a smaH skin biopsy ([5], 
Fig 1). When approaching confluence, the cultured keratinocytes 
can be detached as an epithelial sheet and returned to the donor as an 
autologous skin graft (Fig 1). This technique has been widely em. 
ployed in the treatment of severe burns [17]. The fact that such 
grafts can persist for several years [18], suggests that a significant 
number of stem cells are present in these cultures. In vitro studies 
confirm this idea, and have identified populations of keratinocytes 
with varying growth potential [19]. These have been termed para. 
clones [19], which have the greatest proliferative potential, and 
holoclones, or transit amplifying cells [20] ' which have only limited 
proliferation capacity. Moreover, recent work on these proliferative 
populations suggests that the stem cell residing in the paraclone 
populations [19] may express characteristic surface markers such as 
specific integrins [21]. Thus, it may be possible to potentially sepa. 
rate stem cells (eg by tluorescence-activated cell sorting [FACSI) in 
vitro, prior to introduction of the gene [21]. This would be a signifi. 
cant advantage over an in vivo approach, as greater numbers of trans· 
duced stem cells would increase the chances of long term therapeu­
tic effects. 
Another advantage of the ex vivo approach over the in vivo, is the 
potential to apply selection techniques for transfected cells to ensure 
integration (Fig 1). However, the usual methods of in vitro gene 
transfer (electrophoresis, polybrene, lipofection, calcium phos­
phate) followed by selection, are ineffective due to low transfection 
frequencies. Therefore, the logical alternative is retroviral mediated 
gene transfer and, to date, most clinical trials are based on the use of 
replication defective murine retroviruses [1]. What makes them so 
advantageous is that not only do nearly 100% of replicating cells 
become infected [22], but also the DNA becomes stably integrated 
ito the target genome, insuring its presence in the descendants of 
each infected cell. 
Retroviruses are RNA viruses that reverse transcribe their ge­
nome into DNA that then integrates into the host chromosomes 
[23]. Thus transcription of viral genes, RNA processing, and encap­
sidation are regulated by both viral genes and host cell factors [23]. 
Retroviral mediated gene transfer requires two components. The 
first is the packaging cell line [24], which contains a retroviral 
genome that produces the viral proteins for virion formation, but 
contains a defective signal for encapsidation and therefore cannot 
produce infectious virus particles. A retroviral vector is then trans­
fected into this packaging cell line. The gene of interest replaces the 
viral protein coding genes, but the vector retains functional encapsi­
dation and replication signals. Any combination of promoter and 
gene can be inserted into the retroviral vector, which also usually 
contains a selectable marker, such as the neomycin resistance (neo) 
gene that confers resistance to the neomycin analog G418. The 
packaging cell line then assembles this vector into an infectious viral 
particle. Thus, it is the nature of the packaging cell line that deter­
mines the infectivity range, with ecotrophic virus being centered on 
one species only, whereas the more useful amphotrophic varieties 
can infect most mammalian species, which allows animal testing 
prior to use in humans. Usually, the size of the gene cloned into 
these vectors is limited to 7 kb or less, necessitating the use of 
cDNAs, otherwise viral titers become reduced [25] .. 
Using this ex vivo approach, several laboratories have pioneered 
the use of retroviral mediated gene transfer into proliferating kerati­
nocytes towards a strategy of using the epidermis as a bioreactor 
([26,27]' and below). Another advantage for using the epidermis is 
that the packaging fibroblast cell line can also be employed as the 
feeder layer for the cultured keratinocytes, thus increasing trans­
duction frequencies. Recent results are encouraging, and suggest 
that epidermal stem cells are not only readily transduced, but that 
these genetically altered cells are long lived. In one study, single 
clones of transduced cells were expanded to 109 cells prior to senes­
cence [22] and, in another. canine keratinocytes, transduced with 
the neo gene, were shown to persist as a graft for up to 120 d [14]. 
Furthermore, canine keratinocytes cultured from these grafts re-
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Figure 2. A schematic of an ilt IIillo approach employing the epider­
mis. Several simple in vivo routes exist for most tissues, e.g., systemic injec­
tion or injection directly into the tissue. The epidermis however easily lends 
itself to very novel approaches. The first method utilizes particle bombard­
ment with the gene gun. This method involves coating DNA to gold parti­
cles approximately 1-3 microns in diameter, and projecting these particles 
directly into the skin at high velocity [45]. The second approach utilizes 
topically applied vector transporters, i.e., gene cream, which, depending on 
its make-up, mayor may not require the exposure of poliferative basal cells 
by tape stripping or penetration enhancers. 
tained expression of the neo gene, suggesting that a gene regulated 
by viral promoters could remain active for long periods in keratino­
cytes ([14J see below). 
Although retroviral vectors are to date the mainstay of cell trans­
duction, several features may limit their usefulness. The most sig­
nificant is the potential for generating replication-competent virus, 
although this problem has been reduced with the advent of im­
proved vectors and packaging cell lines [24J. Another safety consid­
eration is the potential for insertional mutations, due to the random 
integration of the viral construct into important loci producing 
unfavorable consequences. Moreover, it is difficult to predict the 
influence of surrounding sequences at the integration site on the 
expression characteristics of the therapeutic gene. Retroviral virion 
particles are also relatively unstable in comparison to other viruses 
and purification often leads to loss of infectivity [2J. In addition. 
amphotrophic retroviruses are readily inactivated in vivo in primates 
[28J, which has significant implications for in vivo approaches 
(below) using retroviral mediated transfer. Furthermore, retrovi­
ruses cannot be made synthetically, they must be produced by living 
cells, which would be costly on a large scale. Some of these problems 
can be overcome by using alternative viral vectors (reviewed in [2]), 
a\tb.ough these are less well developed. For instance, the use of 
adeno-associated virus (AA V), which is known to specifically inte-
IJjJ21"e into a region of human chromosome 19, would minimize the 
deleterious effects of insertional mutations [1,2J. Human papilloma 
viruses (HPV) are also potential candidates for gene therapy vectors, 
as they specifically infect stratifying epithelia and have the advan­
tage of replicating as an episome [16J. Indeed, a vector based on the 
related bovine papilloma virus has been successfully tested in mur­
ine cells [29J. With the advent of successful HPV replication in 
cultured human keratinocytes [30J, it is anticipated that HPV de­
rived vectors will be employed for ex vivo gene therapy. 
I" VIllo Gene Therapy: Viral and Non-Viral Delivery Systems 
The accessibility of the epidermis makes it an attractive target for 
development of in vivo gene therapies (Fig 2). An in vivo approach 
has significant advantages over the ex vivo systems not only from a 
commercial view point, with elimination of costly culture systems, 
but from a clinical point of view also, where the culture require­
ments would limit patient treatment to advanced medical centers. 
The goal then is to achieve the highly desirable genes in a bottle for 
affordable therapy in basic clinical settings. Currently, the l113jor 
'-.&e to in vivo gene tberapy is tbe problem of getting tbe DNA 
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into the vicinity of the target cell prior to transduction. Various 
methods have been I'roposed, ranging from ballistic projectiles, the 
so called gene gun (Fig 2), to simple injection, either systemically 
or directly into a specific tissue. For the epidermis. topical applica­
tion of a vector transport system (i.e., a gene cream) is also an 
exciting but speculative alternative. 
The majority of in vivo studies to date center on the use of retro­
viral vectors for gene transfer. Retroviral vectors have been injected 
. directly into either diseased tissue. e.g., to treat malignant tumors 
[31 J, or into the systemic circulation, with a view to express genes in 
the liver [32J. For an in vivo epidermal approach, to maximize the 
infectivity, it l113y be necessary to expose the basal cells, e.g., via tape 
stripping of the superficial layers or scarring and simply apply a 
retroviral vector topically (Fig 2). To date, we have had reasonable 
success using this technique on mouse skin to introduce the p-galac­
tosidase (pgal) reporter gene (Greenhalgh et ai, manuscript in prepa­
ration). There are three significant problems. The first is that viral 
titers higher than 107 cfu cannot be achieved, thereby limiting in­
fection efficiency. Secondly, cells must be dividing for infection 
[33J. This is a serious limitation for an in vivo retroviral mediated 
approach because it also requires that the stem cells be undergoing 
mitosis [33]. On occasion, however, this facet may be advantageous, 
especially in the treatment of cancer where a suicide gene is intro­
duced that kills the ra..eidly dividing cancer cells, but only a mini­
mum of normal cells (L31 J, see below). Thirdly, several studies have 
shown the gradual inactivation of expression from viral promoters 
[4,34], even though the vector DNA remains present [35]. Thus 
again, even if stem cells can be transduced with retroviral vectors at 
reasonable frequencies. maintenance of long term effects may re­
quire multiple treatments. 
A second viral delivery system that has attracted a great deal of 
recent interest is based on adenoviruses [36J. These vectors have the 
advantage in that they do not require the target cell to be mitotically 
active for infection and, moreover. extremely high titers can be 
generated (1011 cfu). Also unlike retroviruses, adenoviruses are rela­
tively stable and can thus be concentrated without significant loss of 
infectivity [2]. Adenoviruses are DNA viruses with a tropism for 
respiratory and oral keratinocytes. Their 35 kb DNA genome en­
codes early and late genes, and the elimination ofE 1 region contain­
ing the EIA and EIB genes, renders the adenovirus replication de­
fective [36] . Thus, the E1 region of an adenovirus vector becomes an 
obvious site for the insertion of an exogenous promoter/gene cas­
sette. To propagate the adenovirus vector it is first transfected into a 
human 293 kidney cell line, which expresses both the ElA and EIB 
proteins, and these act in trans to package the adenovirus vector 
DNA producing the infectious viral particles. Cellular infection by 
adenovirus is achieved by a receptor mediated endocytosis, followed 
by disruption of the endosome and nuclear localization of the ade­
novirus genome, where it remains extrachromosomal [1,2J. To 
date, an adenovirus vector has been employed to transfer the cystic 
fibrosis conductance regulator protein to the respiratory epithelium 
of cotton rats with impressive results [37], and this has rapidly led to 
clinical trials with the hope of alleviating the pulmonary manifesta­
tions of cystic fibrosis. In preliminary experiments, we found that 
topical infection of scarred, murine epidermis with an adenovirus 
vector carrying a pgal reporter produced high numbers of infected 
cells, and even direct injection of this adenovirus vector into tumor 
tissue resulted in an impressive number of cells expressing pgal 
(Greenhalgh et al., manuscript in preparation). The major problem 
with adenovirus based vectors is the lack of viral integration [2J. 
Thus, any potential therapeutic benefit of expression is limited to 
the differentiation transit time of the infected keratinocytes. For 
long term gene therapy, this failure to integrate is a significant 
drawback, but the adenovirus hexon proteins remain useful for re­
ceptor mediated delivery (below). 
Although the main emphasis in gene delivery centers on viral 
transfer, a great deal of interest is being generated in the develop­
ment of non-viral systems. Such methods are attractive because they 
do not impart any viral sequences into the cell and lend themselves 
to large scale manufacturing. There are several approaches available 
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including, receptor-mediated transfer, liposomal transfer, ballistic 
transfer and injection of DNA/calcium phosphate coprecipitates 
[1,2,38]. Receptor mediated transfer is achieved by linking the 
DNA to a protein ligand via polylysine. These complexes can then 
be injected into the blood stream and will target cells that express 
the protein ligand receptor, allowing the complex to gain entry into 
the cell by endocytosis. To date, the liver system has been the most 
characterized model, being targeted via genes cotYugated to trans­
ferrin [39]. The major advantage of this process is that it results in a 
very efficient method of gene transfer necessary for systemic deliv­
ery. Unfortunately, a significant drawback is that once endocytosis 
has occurred, the endosomes are transported to lysosomes where the 
DNA is subjected to degradation reducing transduction frequencies. 
To overcome this problem several groups have cleverly utilized the 
observation that adenoviruses disrupt endosome function [40,41], 
and have combined this adenovirus function with the receptor me­
diated transfer technique. With this approach plasmid DNA (of any 
size) is linked to an appropriate ligand via polylysine and this com­
plex is then conjugated to the adenovirus by an antibody specific to 
the adenovirus hexon protein [40,41]. Thus, any cell expressing a 
desired receptor, can be transduced with high frequency and, fol­
lowing endocytosis, the adenovirus protein disrupts the endosome 
before any DNA damage occurs. As only adenovirus proteins are 
required, no viral genes are transmitted. This technique has in­
creased transfection efficiency over 1000 times. Indeed, in a recent 
study by Christiano and co-workers [41], 100% of primary hepato­
cytes were transduced in vitro. In villO experiments are eagerly antici­
pated to test long term persistence and expression of introduced 
genes. For the epidermis one can envisage the use of specific ligands 
that target only keratinocytes, e.g., via keratinocyte growth factor 
r42]. In the future it may be possible to use this technique with 
figands that are specific for keratinocyte stem cell receptors. 
The accessibility of the epidermis is also ideal for the afplication 
of lieosomal and ballistic gene transfer techniques (Fig 2). Liposo­
mal/DNA complexes have been widely used in vitro and are capable 
of direct gene transfer in vivo [431. Currently, a clinical trial that 
involves liposome mediated transfer of a major histocompatibility 
gene directly into tumors to enhance immunologic tumor regres­
sion is in progress [44]. Liposomes are associated with a minimal 
toxicity [43] and function by fusing to the cell membrane and re­
leasing DNA into the cytoplasm. Here there is no specificity to the 
type of cell transduced, therefore sfecific expression must rely on 
the promoter employed (see below). By choosing the appropriate 
lipid for the liposome DNA complex and a second for penetration of 
the hydrophobic cutaneous layer, one may generate an epidermal 
gene cream for topical vector delivery (Fig 2). Such delivery sys­
tems are still in their infancy, however, the ballistic approach has 
already been employed to achieve expression in skin l45]. In this 
regime, DNA coated microscopic gold particles are accelerated by 
an electric discharge into living cells. An advantage here is that this 
gene gun approach requires minimal manipulation of the patient or 
target site. Because this is a physical procedure, it is also indifferent 
to the target cell type or its properties. 
EXPRESSION OF EXOG ENOUS G EN ES: VIRAL AND 
ENDOG ENOUS PROMOTE� 
An important consideration for gene therapy is the promoter/en­
hancer cassette chosen to regulate the expression of the therapeutic 
gene. Usually, a high level of expression is required and, for safety 
considerations, it is advantageous to restrict expression to the epi-' 
dermal keratinocytes. In addition, inducible genetic elements could 
be introduced into a composite cassette to enable regulation of dos­
age. High levels of transcription have been achieved through the 
use of viral promoters such as those of retroviruses or the cytomega­
lovirus (CMV) [25]. These promoters are excellent for transient 
expression at high levels and have been chosen for the treatment of 
neoplasms [31]. One problem with viral promoters is their down 
regulation in mammafian cells.[34,35], and, therefore, even in sys-
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tems where persistence of the exogenous gene was observed[14,35] 
expression levels were reduced [14] and eventually disappeared [35]. 
However, this was not the case for gene bombardment into rat skin, 
where dermal cells had extended levels of expression from the CMV 
promoter [45]. This suggests the possibility that viral promoter 
inactivation may be dependent upon cell type, means of delivery, 
and the nature of the viral promoter itself. It has also been shown 
that non-viral promoters can be silenced when situated downstream 
from a viral promoter [34]. 
These problems can potentially be overcome by using mamma­
lian promoters. Because several genes have been characterized with 
epidermal-specific expression, a variety of promoters are available 
for targeting exogenous gene expression to the integument. Thus, 
not only can promiscuous expression be prevented in a non-target 
tissue, but expression can be directed to specific epidermal strata and 
appendages. In particular, use of specific keratin gene control ele­
ments gives a significant targeting flexibility [6]. Depending upon 
therapeutic requirements, it may be desirable to target basal cells, 
thus a K14-based vector would be useful [8]. Alternatively, it may be 
necessary to restrict expression to suprabasal cells, e.g., by employ­
ing a K10-based promoter [9]. Where high levels of expression are 
required (i.e., where the epidermis is employed as a bioreactor), the 
truncated, HK1-based vector developed in our laboratory may be 
useful since it has expression in both basal and differentiated cells 
[7]. Moreover, this is epidermal specific [7], whereas other keratins 
are expressed at other sites [6,8,9], which may not be desirable. For 
inducible promoters/vectors, the K6 keratin is an attractive candi­
date, as its expression is induced by a variety of stimuli includ­
ing wounding, tape stripping, and retinoid application [6]. Of 
course any one of the keratin based vectors could become steroid 
or retinoid sensitive by including the appropriate genetic ele­
ments [46]. 
DISEASES AMENABLE TO EPIDERMAL GEN E THERAPY 
Correction of Inherited Skin Disorders Of the genetic dis­
eases known in man, about 5% have been associated with a skin 
phenotype [47], but only in a few of these diseases have the molecu­
lar defects been defined. One reason for the limited progress in this 
area is that many skin disorders display similar clinical symptoms, 
yet are genetically very heterogeneous. Recendy, several groups 
have identified the genetic defect underlying epidermolytic hyper­
keratosis (EHK) and epidermolysis bullosa simplex (EBS) (reviewed 
in [11]). EBS and EHK have been common features, including 
intra-epidermal blistering due to cytolysis of keratinocytes. Ultra­
structurally, these diseases are characterized by a collapse of the 
keratin filament network, which aggregates around the nucleus as a 
perinuclear shell or as cytoplasmic clumps. In EBS, the collapse of 
the filament network is limited to the cells of the basal layer whereas 
the suprabasal cells are uninvolved. Given the observation that trun­
cated keratins expressed in cultured cells resulted in a perturbed 
intermediate filament network [48], researchers focused attention 
on the keratins of EBS and EHK patients. For EBS, point mutations 
were found in the coding regions of the genes for K5 and K14, and 
for EHK, we and others have identified mutations in the highly 
conserved regions of both K1 and K10 (reviewed in [11]). 
What then are the options for a gene therapy approach? Obvi­
ously, the ideal therapy would result in repair of the mutated gene 
by homologous recombination. Unfortunately, this is not likely to 
be practical in the near future. One approach, therefore, would be to 
inhibit expression of the mutant allele. This may be achieved using 
antisense RNA or ribozymes expressed from KS/K14-based vectors 
for EBS or Kl/K10-based vectors for EHK. Alternatively, over-ex­
pression of the normal protein may be efficacious. A major limita­
tion of these approaches is the requirement for transducing high 
numbers of cells, including an adequate proportion of stem cells. 
However, given the high transduction efficiency of receptor me­
diated/adenovirus protocols (above), one can certainly expect a sig­
nificant therapeutic, if temporary, benefit from transducing 50% of 
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the cells in a given lesion. As inherited skin diseases become more 
fully understood, the development of animal models that mimic the 
disease will be vital to help address the efficacy of putative treat­
ments [49]. 
Treatment of Skin Cancer The incidence of skin cancer ap­
proaches that of all other malignancies combined [15]. Although 
there are viable surgical procedures that readily eliminate skin neo­
plasms, gene therapy would be a useful alternative, especially for 
tumors that occur at difficult to treat locations, those that are unusu­
ally large, and those that are metastatic. There are several ways to 
employ gene therapy for neoplastic disease, including melan�nia. 
They fall into two basic categories: 1) a generic therapy, where an 
exogenous gene enhances immunologic surveillance or induces 
tumor cell death; and 2) specific therapies. where the gene(s) re­
sponsible for the neoplasm are targeted for modulation. Of the 
methods to attack the tumor per se, an ex vivo approach to produce a 
tumor vaccine can be taken. Here tumor cells can be transduced 
with, eg vectors expressing tumor necrosis factor [3] or cytokines 
(e.g., interleukin 2 (IL-2), interleukin 4 (IL-4) or granulocyte/ 
macrophage -colony-stimulating factor (GM-CSF)) to elicit a more 
vigorous immune response upon introduction back to the patient. 
Direct in vivo transduction however is probably more useful, and in 
this case a retrovirus-mediated transduction may be the ideal means 
to achieve the introduction of anti-tumor genes. This takes advan­
tage of the fact that retroviruses only infect dividing cells. Thus, 
using this approach, normal quiescent cells would not be affected. 
Also, by using a keratinocyte or melanocyte specific promoter, the 
toxic effect of a suicide gene would also be more restricted to tumor 
cells. The problem is that simple injection of virus may be insuffi­
cient to transduce all tumor cells. This can be alleviated somewhat 
by injecting the viral producer cells themselves to improve trans­
duction efficiency [31]. In initial in vivo testing in animals, scientists 
have utilized the herpes simplex virus thymidine kinase (HSV -TK) 
gene as a suicide gene. The HSV -TK protein converts the nucleo­
tide analogue, gancyclovir, into a toxic molecule and as a tumor cell 
dies it releases this toxin to other non-transduced cells, ie the by­
stander effect. Thus, brain tumors in rats were shown to regress 
completely when HSV -TK packaging cells were injected into the 
tumor followed by systemic injection of gancyclovir for 5 d [31]. 
This approach, using a melanocyte specific tyrosinase promoter 
coupled to HSV -TK, also successfully inhibited experimental mur­
ine melanomas [38]. 
The more specific approach is dependent on identifying the cru­
cial genes involved. Carcinogenesis is a multistage process involv­
ing cooperation between oncogenes (normal genes becoming acti­
vated), and tumor suppressor genes (normal genes becoming 
inactivated or altered in function). In skin, especially on sun exposed 
areas, two genes would seem to be prime candidates for interven­
tion. UV -induced point mutations have been detected in the rasHa 
oncogene [50] and the p53 tumor suppressor gene [51]. These can be 
early events present in benign lesions, thus presenting an opportu­
nity for therapeutic intervention prior to overt malignancy. Over­
expression of the normal p53 gene may be efficacious, possibly 
inducing apoptosis [52]. For rasHa, dominant negative mutants that 
interact only with the activated oncogenic rasHa p21 protein in 
membrane signaling have been described [53]. Thus, over-expres­
sion of these mutants would allow therapy to be restricted to tumor 
cells expressing an activated rasHa oncogene. As transgenic model 
systems for carcinogenesis are developed that increase our under­
standing of carcinogenesis in vivo [7-9,54-57], new avenues for 
gene therapy intervention will undoubtedly arise. 
Employing the Epidermis as a Bioreactor for Disease 
Treatment In addition to its function as an external barrier, the 
epidermis also secretes a variety of factors, eg vitamin D3, growth 
factors and cytokines, that act at both local and distant sites (see [58] 
for a recent review). This raises the possibility that the epidermis 
could be used as a bioreactor to produce proteins for systemic release 
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to treat disease. At this time it is not clear whether all proteins 
secreted by the epidermis can achieve systemic distribution. This 
critical feature may depend upon the protein size, type (hydropho­
bic/hydrophilic), and the requirement for peptide signals to cross 
cell or tissue barriers. Human keratinocytes have already been 
shown to secrete biologically active proteins following retroviral 
transduction and grafting onto nude mice. One of the first studies 
introduced human growth hormone (hGH [26]), unfortunately, 
whereas hGH protein was detected at the graft site, no circulating 
protein was detected. This may have been a consequence of the 
insensitivity of the assay [26], as another study demonstrated that 
large molecules such as apolipoprotein E (apo E), could be secreted 
into the bloodstream by grafted human keratinocytes [59]. Indeed, 
in a recent study testing the possibility of using the epidermis as a 
bioreactor for the treatment of hemophilia B, factor IX was secreted 
into the bloodstream following transplantation of transduced 
human keratinocytes onto nude mice. However, long term expres­
sion was not sustained in the circulation. Thus, functional use of the 
capacity of the epidermis to act as a bioreactor awaits significant 
progress in developing/maintaining high levels of secretion from 
keratinocytes in vivo and understanding the kinetics of dermal trans­
port. 
CONCLUSIONS: SAFETY AND FUTURE PROSPECTS 
The safety considerations for gene therapy must be compared to any 
potential benefit. For retroviral transduction in particular (reviewed 
in [60]), the possibility of generation of replication competent virus 
is a serious threat, one that has already resulted in development of 
T-cell lymphomas in Rhesus monkeys [61]. For this reason, all 
retroviral protocols should include assays to assess for helper virus, 
and new packaging lines that are designed to minimize this leakage 
[24]. Avoiding this method of transduction eliminates the problem, 
and furthermore, use of DNA receptor-mediated transduction 
completely eliminates the need for viral genes. However, for nearly 
all transduction techniques, insertional mutagenesis occurs, with 
the potential for deregulation of endogenous genes, e.g., oncogenes 
or tumor suppressors. Only by maintaining the transduced DNA as 
an episome can this be avoided. Given these potential problems, it is 
immediately obvious that the epidermis has an easily applied, inher­
ent safety technique, i.e., removal of the treatment area/graft site. In 
addition, relevant model systems must be developed to directly test 
the delivery and efficacy of a particular gene therapy in vivo prior to 
clinical trials in humans. Currently testing is limited to in vitro assays 
employing primary human keratinocytes, and these studies have 
reported that there are no obvious deleterious effects (immortaliza­
tion, transformation) of introducing a retroviral vector [62]. Al­
though this is encouraging, an in vitro assay, even including a nude 
mouse graft analysis, may not fully predict the in vivo result. For 
instance, retroviral TGFa introduction ex vivo into primary kerati­
nocytes gave no obvious effect in nude mouse grafts [63], but in 
transgenic mice, epidermal over-expression of TGFa resulted in 
hyperplasia and papillomas [8,56]. Thus, the ability to target gene 
expression to the epidermis of transgenic mice provides a powerful 
tool to assess the safety considerations of a particular gene therapy. 
Also, as outlined above for the epidermis, several transgenic mouse 
models of diseases already exist [7 -10,49,54-57] that represent 
ideal opportunities to test both delivery and efficacy of a novel gene 
therapy. 
The great potential for gene therapy to treat genetic and acquired 
diseases is revealed in the speed by which the field, and indeed 
clinical trials, have evolved. It can only be a matter of time before 
gene therapy is widely applied. To achieve viable epidermal gene 
therapy, advances in in vivo transduction are required to maintain 
stable, long term expression. The transduced gene needs to be able 
to integrate into a safe non-critical site within the genome or be 
maintained as a replicating episome, and its expression needs to be 
responsive, when necessary, to extracellular (topical or systemic) 
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signals. Thus, whereas in this decade gene therapy is in its infancy, 
in the next century a whole new meaning could be attached to the 
term designer genes. 
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